Oct 21, 2020 8:30am EDT Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders
Oct 14, 2020 4:05pm EDT Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option
Oct 09, 2020 8:30am EDT Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering
Sep 29, 2020 8:00am EDT Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia
Sep 11, 2020 9:00am EDT Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
Sep 10, 2020 9:15am EDT Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit
Aug 26, 2020 9:30am EDT Artelo Biosciences to Present at The LD 500 Virtual Investor Conference on September 1st
Jul 14, 2020 9:25am EDT Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update
Jun 29, 2020 8:30am EDT Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds
Jun 03, 2020 9:30am EDT Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences
